Immunoglobulin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the immunoglobulin market size is projected to expand from USD 17.27 billion in 2025 and USD 18.39 billion in 2026 to USD 25.15 billion by 2031, registering a CAGR of 6.46% between 2026 to 2031.

This report is Segmented by Product (IgG, Iga, Igm, Ige, Igd), Mode of Delivery (Intravenous, Subcutaneous, Intramuscular), Application (Hypogammaglobulinemia, CIDP, Primary Immunodeficiency Disease, and More), Distribution Channel (Hospital Pharmacies and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Immunoglobulin Market Trends and Insights

Rising Prevalence of Primary Immunodeficiency Diseases

Newborn screening and next-generation sequencing are revealing 40% more primary immunodeficiency cases than earlier estimates, expanding the eligible patient pool for lifelong replacement therapy. Insurance mandates in the United States and Western Europe cut time-to-diagnosis from eight years to under 18 months, yet Asia-Pacific lags by up to seven years despite China's pilot programs that may add 15,000-20,000 new diagnoses annually by 2029. Earlier detection lowers per-dose volumes but extends treatment duration, magnifying cumulative plasma demand. The resulting strain reinforces manufacturer investment in collection centers even as reimbursement shifts care out of hospitals. Sustaining this driver beyond 2028 will depend on ongoing declines in genetic testing costs and parallel reimbursement expansion.

Growing IVIG Use in Neurology (CIDP, GBS, MMN)

FDA guideline updates in early 2025 positioned IVIG ahead of corticosteroids for chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, and multifocal motor neuropathy. Japan's December 2024 approval of HYQVIA enabled monthly home dosing that bypasses intravenous access, accelerating neurologist uptake. Off-label adoption in stiff-person syndrome and autoimmune encephalitis is broadening demand, though high doses intensify plasma-supply competition and elevate annual therapy costs to USD 80,000-120,000. European payers now require head-to-head data versus rituximab, which could temper growth after 2028. Near-term, neurology adds 1.5 percentage points to the Immunoglobulin market CAGR.

High Therapy Cost & Reimbursement Gaps

Annual immunoglobulin therapy costs range from USD 50,000 for maintenance immunodeficiency to USD 120,000 for high-dose neurology, leaving most patients in Latin America and parts of Asia without coverage. Argentina's reimbursement queue stretches up to nine months, and Brazil rationed supply during 2024-2025 shortages. Because 70% of manufacturing expense arises before final fill-finish, price cuts are structurally difficult. Payers in developed markets now mandate home infusion to shave 30-40% off facility fees, but the underlying plasma cost persists, deterring new capacity investment.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of Global Plasma-Fractionation Capacity
2. On-Body High-Concentration SCIG Devices for Home Therapy
3. Fc-Engineered Monoclonal Antibodies as Therapeutic Substitutes

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

IgG held 43.55% of Immunoglobulin market share in 2025 on the strength of entrenched use across immunodeficiency and hematologic disorders. High-concentration IgG formulations such as Cuvitru reduce infusion time by half, boosting home-based adherence. IgE therapies, though nascent, are projected to outpace the broader Immunoglobulin market at a 9.85% CAGR on emerging eosinophilic applications. IgA and IgM remain niche but benefit from selective IgA deficiency cohorts that cannot tolerate standard products. Limited regulatory clarity for IgE endpoints tempers near-term launch certainty.

Manufacturers with advanced purification can command premium pricing for stable 20% products, yet hyaluronidase co-formulation adds USD 500-800 per dose, complicating payer negotiations. Regulatory lag for novel IgE and IgM programs may delay revenue until after 2029, but pipeline diversity positions the product mix for gradual broadening beyond IgG dominance.

Intravenous immunoglobulin retained 64.53% revenue share in 2025 thanks to decades of clinician familiarity and hospital infusion infrastructure. Nevertheless, subcutaneous immunoglobulin is forecast to expand at 10.75% CAGR, reflecting payer push to lower facility costs and patient preference for at-home convenience. The Immunoglobulin market size linked to SCIG is poised to grow steadily as device interoperability standards mature.

Reimbursement misalignment slows transition: U.S. Medicare pays 20-30% less for subcutaneous products, and prior-authorization resets add bureaucracy. Patient self-training costs and real-time temperature monitoring further squeeze margins for specialty pharmacies. Despite these headwinds, weekly self-administration and lower adverse-event incidence support ongoing mode-shift momentum.

Complete Report Scope:

• By Product
  • IgG
  • IgA
  • IgM
  • IgE
  • IgD
• By Mode of Delivery
  • Intravenous (IVIG)
  • Subcutaneous (SCIG)
  • Intramuscular
• By Application
  • Hypogammaglobulinemia
  • Primary Immunodeficiency Disease (PID)
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Myasthenia Gravis
  • Immune Thrombocytopenia Purpura (ITP)
  • Other Applications
• By Distribution Channel
  • Hospital Pharmacies
  • Specialty / Retail Pharmacies
  • Online & Home-Infusion Providers
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America remained the largest regional contributor with 44.55% revenue share in 2025 on unrivaled per-capita usage and over 900 licensed plasma centers. Growth is moderating to mid-single digits as donor saturation and payer pressure constrain expansion. Europe follows, where EMA's 2024 pathogen-safety upgrade lengthened batch-release cycles by up to six weeks and lifted spot prices 15-20%.

Asia-Pacific is the fastest-growing territory at 7.72% CAGR, propelled by China's new export-quality certifications and Japan's CIDP-focused HYQVIA launch. India's Immunoglobulin market faces infrastructure and affordability gaps, limiting rural reach. Australia and South Korea track mature-market trends at 4-5% growth while expanding newborn screening.

South America and the Middle East trail amid funding constraints, though Gulf Cooperation Council countries are widening rare-disease budgets. Supply rationing in Brazil and Argentina underscores cost barriers and justifies manufacturers' vertical-integration push. Africa's demand is small but rising with concentrated initiatives in South Africa and Nigeria to address severe combined immunodeficiency.

1. ADMA Biologics
2. Baxter
3. Bio Products Laboratory (BPL)
4. Biotest
5. China Biologic Products
6. CSL Behring
7. Emergent Bio Solutions
8. GC Biopharma
9. Green Cross Corp.
10. Grifols
11. Hualan Biological Engineering
12. Kamada Ltd.
13. Kedrion Biopharma
14. LFB Group
15. Octapharma
16. Pfizer
17. Sanquin
18. Shanghai RAAS Blood Products
19. Takeda Pharmaceutical Co.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support